Comparative evaluation of the erbB2 and hormone receptor status of neighboring invasive and in situ components of ductal carcinomas of the breast

dc.creatorPeres, RMR
dc.creatorSerra, KP
dc.creatorDerchain, SFM
dc.creatorYoon, JH
dc.creatorPinto, GA
dc.creatorAlvarenga, M
dc.creatorSoares, FA
dc.creatorHeinrich, JK
dc.creatorda Cunha, IW
dc.creatorVassallo, J
dc.creatorSarian, LO
dc.date2009
dc.dateOCT-DEC
dc.date2014-11-15T18:19:23Z
dc.date2015-11-26T17:21:14Z
dc.date2014-11-15T18:19:23Z
dc.date2015-11-26T17:21:14Z
dc.date.accessioned2018-03-29T00:08:45Z
dc.date.available2018-03-29T00:08:45Z
dc.identifierInternational Journal Of Biological Markers. Wichtig Editore, v. 24, n. 4, n. 238, n. 244, 2009.
dc.identifier0393-6155
dc.identifierWOS:000276825300004
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/79147
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/79147
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/79147
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1283319
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionBackground: It remains unknown whether erbB2 expression and hormone receptor status predict the invasive potential of ductal carcinoma in situ (DCIS) of the breast. Objectives: To examine erbB2 and estrogen/progesterone receptor (ER/PR) status in the precise areas where DCIS turns into invasive ductal carcinoma (IDC). Subjects and methods: Eighty-seven cases of breast malignancies harboring contiguous regions of DCIS and IDC were selected. Separate histological samples from the DCIS and the neighboring IDC were obtained using tissue microarrays. The erbB2 and ER/PR statuses were assessed using immunohistochemistry (erbB2 and ER/PR) and fluorescence in situ hybridization (FISH only erbB2). Results: The expression of erbB2 did not differ in the DCIS and IDC components of the breast tumors (p=0.35). There was good agreement in sample-by-sample comparisons of erbB2 (intraclass correlation coefficient [ICC]=0.78), PR (ICC=0.61) and ER (ICC=0.70) expression in the DCIS and IDC components. Conclusion: Our findings suggest that the expressions of erbB2 and ER/PR do not differ in the contiguous regions from DCIS to IDC. (Int J Biol Markers 2009; 24: 238-44)
dc.description24
dc.description4
dc.description238
dc.description244
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionFAPESP [2008/08536-9, 2008/02469-8]
dc.languageen
dc.publisherWichtig Editore
dc.publisherMilan
dc.publisherItália
dc.relationInternational Journal Of Biological Markers
dc.relationInt. J. Biol. Markers
dc.rightsfechado
dc.sourceWeb of Science
dc.subjectBreast
dc.subjecterbB2
dc.subjectCancer
dc.subjectEstrogen receptor
dc.subjectProgesterone receptor
dc.subjectEstrogen-receptors
dc.subjectCancer
dc.subjectMarkers
dc.subjectCategorization
dc.subjectProgression
dc.subjectExpression
dc.subjectHer2
dc.titleComparative evaluation of the erbB2 and hormone receptor status of neighboring invasive and in situ components of ductal carcinomas of the breast
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución